Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has established a new subsidiary in Sydney, Australia. Through this move, Sysmex aims to enhance its sales and support networks in Australia and expand its business.
Australia's healthcare expenditure of the country has been increasing at 6% average growth from 2008 to 2012. Average growth for healthcare expenditure per-capita is 4.3%.
To date, Sysmex has been selling its products and providing service support in Australia via business partners, Roche for the field of hematology, Siemens for hemostasis and bioMerieux for urinalysis. Sysmex have developed our business by leveraging these companies' sales and support networks.
Our objective in establishing a new subsidiary in Sydney is to provide the products which meet clients' needs and to enhance the presence of Sysmex in the market.
In addition to selling products and providing service support via business partners, we will commence direct sales in the IT field, such as laboratory information systems developed by our affiliate in New Zealand, aiming to provide services and support which enhance efficiency of testing in a manner distinctive to Sysmex.
Furthermore, we plan to begin direct sales of Partec (Now Sysmex Partec) products, which became a Sysmex subsidiary in 2013, and accelerate the expansion of this business.
Going forward, Sysmex aims to augment its sales and support structure and provide Sysmex-specific service support globally, as it strives to contribute to the development of healthcare.
|Outline of Sysmex Australia
Sysmex Australia Pty Ltd.
|Capital supplied by:
||Sysmex Asia Pacific
(Sysmex Asia Pacific is a wholly owned subsidiary of Sysmex Corporation)
||6 (planned for fiscal 2014)
|Line of business:
||Sales of in vitro diagnostic instruments, reagents and laboratory information systems, and related after-sales support
- Information contained in the press release is current as of the date of the announcement,
but may be subject to change without prior notice.